Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab in Advanced Melanoma
NCT03958383Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2020
- Primary completion
- Jan 2024
- Modality
- Immunomodulatory ADCs, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of Lorukafusp alfa in melanoma (4 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Incidence of Adverse Events up to 2 years, Maximum Tolerated Dose up to 21 days and 1 more. Started Jan 2020; status: terminated.
02
Drugs
Lorukafusp alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03958383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958383.